VT-362 has been shown to bind CD153 on the surface of human neutrophils, thereby preventing interactions between intact cellular CD30 and CD153.  Early preclinical studies demonstrated VT-362 has the ability to inhibit T-cell activation in vitro, and to prevent the induction of a type 1 (TH1) T-cell response in vivo.